The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...
SAN FRANCISCO--(BUSINESS WIRE)--Vor Systems, an AI-enabled transaction platform built for complex renewable energy deals, today announced it has raised $3 million in pre-seed funding led by Gigascale ...
Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...
Hosted on MSN
Vor Biopharma approves stock option repricing plan
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...
Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Expected gross proceeds of $115 million raised in the November 2025 underwritten public offering, including the underwriters’ full exercise of the option to purchase additional shares BOSTON, Nov. 13, ...
Vor Biopharma (NASDAQ:VOR) has been upgraded to Buy from Hold at Stifel as confidence in the company’s long-term potential has grown following prospects for its lead asset, telitacicept. The shares of ...
On Wednesday, Vor Bio Inc. (NASDAQ:VOR) announced that its collaborator, RemeGen Co., Ltd., achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in ...
The recombinant fusion protein drug telitacicept from Remegen Co. Ltd. and Vor Bio Inc. has notched a phase III win in treating adults with IgA nephropathy. The clinical trial of the fusion protein ...
Dallan Murray joins Vor Bio as chief commercial officer, bringing expertise in commercial strategies and product launches from his time at Sarepta. At Sarepta, Murray contributed to significant ...
Vor Bio has handed Dallan Murray a swift return to the workforce. Weeks after being let go by Sarepta Therapeutics, Murray has landed the chief commercial officer post in Vor’s new-look C-suite.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results